Anthrax Post-Exposure Drugs Need Extensive Marketing History – Draft Guidance
Executive Summary
Drugs should have broad postmarketing experience before sponsors pursue an indication for post-exposure anthrax, a draft guidance from FDA's Center for Drug Evaluation & Research states
You may also be interested in...
Smallpox Sequela FDA Draft Guidance Recommends Data Collection Systems
An FDA draft guidance on developing drugs to treat complications associated with smallpox vaccination lists data collection recommendations for pre-terrorism events, post-terrorism events and post-approval
Smallpox Sequela FDA Draft Guidance Recommends Data Collection Systems
An FDA draft guidance on developing drugs to treat complications associated with smallpox vaccination lists data collection recommendations for pre-terrorism events, post-terrorism events and post-approval
Animal Efficacy Rule Will Be “Flexible” About Species Needed – CBER’s Zoon
FDA will exercise more flexibility in the number of animal species required for testing before approval of counter-terrorism products under the final animal efficacy rule, Center for Biologics Evaluation & Research Director Kathy Zoon, PhD, said